Care
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
Christopher McGhee says that, along with the acquisition, Current Health will have a "return to scrappiness and that startup spirit."
The company offers an AI-enabled workflow automation platform for administrative tasks pertaining to specialty medications.
Connor Glass, founder and CEO of Phantom Neuro, discusses the company's muscle-machine interface that allows individuals with limb loss to control robotic limbs and systems using electrical activity from their own muscles.
Employees will have access to clinical content and more than 900 U.S. clinics that specialize in fertility, urology and menopause.
The company will use the funds to advance its AI-enabled robotic platform for cataract and other eye surgeries, with plans to begin human clinical trials this year.
The Series E funding comes four months after the company secured $250 million in a Series D round.
Selected early versions will be slated for real-world deployment.
HIMSS25
Joan Webley of Hospitals Without Borders, which provides modular hospitals and clinics to regions in need, says attending HIMSS25 helped her gain insights and connect with people interested in the organization's mission.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.